Theralase Technologies Inc. V.TLT

Upcoming patient data

[99942Apophis]

Our expectations of patient data in this upcoming Newsletter should contain results of patients 25 through to and include patient 30 for the period of 90 days.

Also we should receive data on patients 21, 22, 23 and 24  for their 180 period. This will give us a sense of future patients and their success going forward of which in my opinion will score very high.
Much talk lately whether we will hear any hint of other topics of interest as in partnership/partnerships, new patients,  Ph1 of GBM & NSCLC and any advancement in the therapeutic/vaccine story! With recent changes in personal at the company my opinion is we will have better communication in both positive and negative information. Have a good long weekend.

[Oilminerdeluxe]

83 M market cap. I will never understand markets. It's getting really close to the next update. Should be a lot of data in it. Maybe we should change name to Theralase Crypto instead.

[StevenBirch]

I respectfully disagree Oil, we don't want to be some kind of fad that is vulnerable to big swings because those situations very seldom benefit investors like us. When the numbers come in and assuming they are as we expect they will speak for themselves and we will be rewarded.

[Oilminerdeluxe]

Oh , I was just venting som frustrations, StevenBirch :-) I hope Vera gives a few notes next time we here anything. 

[StevenBirch]

Yes I know, me too but I think that's what the manipulators want! Most of us here don't act on that thank god because we are now looking at 5 days +/- before what could be the real launch of TLT. Let's see what Vera has for us beyond NMIBC.

[Oilminerdeluxe]

Fingers crossed. It would feel wonderful to climb closer to $1. Or at least past 50 cents. I don't know what it will take for the share price to take off if data so far has not done it. Perhaps we will simply have to wait for that BTD or perhaps some kind of beneficial j/v out of the blue. But solid data will of course make the wait a bit easier. Not long to go now.

[winr88]

I definitely agree that very positive results for the 180 day and 90 day trials will be reported. I have mixed feelings however how much the share price will increase despite kick A$$ CR results.  I wonder how many in the market are thinking “too good to be true” and are waiting for the other shoe to drop regarding negative health effects or a big correction in trial results to the downside

[CancerSlayer]

  Although I consider myself an educated & objective man, a little superstitious sentiment creeps in from time to time.  I'd hate to see comments re: predictions made by a negative market jinx our results...we can leave that to the sports announcers ; ).  I actually think very few are thinking this tech is "too good to be true".  On the contrary, many think

[Eoganacht]

So to outdo these results Theralase must maintain a greater than 39% CR rate after 18 months. (55% of 71%) Given the results so far that sounds very likely.

[DJDawg]

Another interesting thing about the above graph of durable response (bcg+n-803) is that they hit 55% at 18 months but to my eyes it drops off another few steps so by 27 months it is around 25%. For these kind of graphs you get used to them leveling off as everyone who is in true remission stays that way. To have it keep dropping off makes me think that the CR isn't really a CR in a cure sense.

[StevenBirch]

Great post CS. I have been against some of the competition talk because to me it comes with a negative bias and not because I don't think it exists or it will hurt TLT. You are right we need every available option to treat cancer, mutiple cancers, and  with TLT being in the ballgame there is more than enough to go around to make us happy. I also don't think the market is waiting for

[greaterfoolFred]

I have a question, but am too lazy to find out for myself, and I am sure that most of you already know the answer.  Who are the patients being treated in the "N-803 + BCG for CIS disease" trial.  Have these people already failed BCG treatment (like in our 1433 trial?) Or is this their first treament using BCG?  Thanks, and good luck all.

[CancerSlayer]

  Enrolled patients are BCG-unresponsive.... ClinicalTrials.gov Identifier: NCT03022825

[enriquesuave]

From what I understand from N-803 plus BCG results is they have 62% of CR patients maintaining CR at 12 months post 1st CR that comes out to 44% CR  of all CIS patients (62% of the 71%) at 18 months it's 55% of 71% or 39%  and 52% of 71% or 37% 24 months post 1st CR.  They make it look better than it really is.  But yes it's still very good, but hopefully we can match

[DJDawg]

Hey Enrique. Do you find interesting  the way the graph has several significant steps down right after the 24 m time point?

[Eoganacht]

I think that's the correct interpretation. It's rather deceptive the way they express it. Merck did the same thing when they published the Keytruda results. They don't give the percentage CR of the entire trial population at different times - just the percentage of the original 72% CR who remained CR at 12 months and 18 months.

[CancerSlayer]

Enrique wrote... "From what I understand from N-803 plus BCG results is they have 62% of CR patients maintaining CR at 12 months post 1st CR that comes out to 44% CR  of all CIS patients (62% of the 71%) at 18 months it's 55% of 71% or 39%  and 52% of 71% or 37% 24 months post 1st CR.  They make it look better than it really is.  But yes it's still very good

[langosta]

I can understand opting out, especially considering the age factor of a patient. From personal experience I was diagnosed with an oral cancer at age 83.  I understand this was  a completely different  experience, but my first reaction was, "what the heck, I'm 83 and have had a pretty good life just let it run its course I don't want an operation which may or may not be

[CancerSlayer]

  Thanks for sharing your personal story langosta...glad you opted in & your story (as does gooseybear's) brings to light the importance of having treatment options when dealing with cancer.  Cancer treatment rarely is a one-size-fits-all model, & TLT's unique patient-friendly approach should hopefully make one's treatment decision (doc & patient) a lot easier.

[CancerSlayer]

  NOTE: Although N-803 is not a checkpoint inhibitor, but rather a form of interleukin or cytokine that stimulates an immune response, the drop-off in CR% after 24 months (using N-803 + BCG) suggests a similar process of T cell/immune response exhaustion may be occurring as can happen with checkpoint inhibitors.  The immune response simply can no longer be boosted, which may reflect

[enriquesuave]

It may also be that they don't have much data beyond the 24 months mark?  

[CancerSlayer]

Yep...could be a small sample size at that point.  But my guess is it is more than that...